



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2022/012044

(22) International Filing Date:
11 January 2022 (11.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/136,091 11 January 2021 (11.01.2021) US

(71) Applicant: **ADIMAB, LLC** [US/US]; 7 Lucent Drive,
Lebanon, New Hampshire 03766 (US).

(72) Inventors: **BARLOW, Kyle**; c/o ADIMAB, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). **SI-VASUBRAMANIAN, Arvind**; c/o Adimab, LLC, 7 Lu-

cent Drive, Lebanon, New Hampshire 03766 (US). **BAT-TLES, Michael Benjamin**; c/o ADIMAB, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US).

(74) Agent: **TESKIN, Robin, L.** et al.; BAKER, DONELSON, BEARMAN, CALDWELL & BERKOWITZ, P.C., Intellectual Property Department, 901 K Street, NW, Suite 900, Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: VARIANT CH1 DOMAINS AND VARIANT CL DOMAINS ENGINEERED FOR PREFERENTIAL CHAIN PAIRING AND MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME




FIG. 1A

(57) Abstract: Variant CH1 domains, variant CL domains, and variant CH1-CL domain sets which contain at least one amino acid substitution that promotes preferential CH1-CL pairing are provided. Also provided are polypeptides, molecules, and multi-specific antibodies comprising such variants; and compositions comprising any of the foregoing. Methods of generating a variant CH1 and/or variant CL domain library and methods of using same to identify one or more variant CH1 and/or variant CL domains and/or variant CH1-CL domain sets are also provided. Further provided are methods of screening for a combination of CH1-CL sets suited for multi-specific antibodies and/or antigen-binding antibody fragments.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*